| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 542 | 352 | 10 |
| Full Text Views | 5 | 2 | 0 |
| PDF Downloads | 7 | 3 | 0 |
Clinical Standardization of Pamaquin (Plasmochin) in Mosquito-Induced Vivax Malaria, Chesson Strain
A Preliminary Report
Branch Craige Jr.
Branch Craige Jr.
Malarial Research Unit, Department of Medicine, University of Chicago
Search for other papers by Branch Craige Jr. in
Current site
Google Scholar
PubMed
Search for other papers by Branch Craige Jr. in
Current site
Google Scholar
PubMed
Ralph Jones Jr.
Ralph Jones Jr.
Malarial Research Unit, Department of Medicine, University of Chicago
Search for other papers by Ralph Jones Jr. in
Current site
Google Scholar
PubMed
Search for other papers by Ralph Jones Jr. in
Current site
Google Scholar
PubMed
C. Merrill Whorton
C. Merrill Whorton
Malarial Research Unit, Department of Medicine, University of Chicago
Search for other papers by C. Merrill Whorton in
Current site
Google Scholar
PubMed
Search for other papers by C. Merrill Whorton in
Current site
Google Scholar
PubMed
Theodore N. Pullman
Theodore N. Pullman
Malarial Research Unit, Department of Medicine, University of Chicago
Search for other papers by Theodore N. Pullman in
Current site
Google Scholar
PubMed
Search for other papers by Theodore N. Pullman in
Current site
Google Scholar
PubMed
Alf S. Alving
Alf S. Alving
Malarial Research Unit, Department of Medicine, University of Chicago
Search for other papers by Alf S. Alving in
Current site
Google Scholar
PubMed
Search for other papers by Alf S. Alving in
Current site
Google Scholar
PubMed
Lillian Eichelberger
Lillian Eichelberger
Malarial Research Unit, Department of Medicine, University of Chicago
Search for other papers by Lillian Eichelberger in
Current site
Google Scholar
PubMed
Search for other papers by Lillian Eichelberger in
Current site
Google Scholar
PubMed
Summary
Several regimes of pamaquin (plasmochin) were given a therapeutic trial in mosquito-induced vivax malaria (Chesson strain).
The administration of daily doses of 63 milligrams of the base or 140 milligrams of the naphthoate salt, or less, concurrently with quinine for 14 days protected only a few of the subjects against relapse. No protection was afforded when the drugs were given serially. The effect was not appreciably enhanced when pamaquin (31 milligrams of the base a day) was administered concurrently with several other experimental drugs.
The average percentage of total hemoglobin converted to methemoglobin was a useful measure for the comparison of the toxicity of various regimes of pamaquin.
Standardized clinical trials diminished the influence of variables, such as acquired and natural immunity, variations in intensity of infection, the effect of suppressive drugs, and strain differences, which confuse the interpretation of results in field studies.
Author Notes
Captain, M.C., A.U.S.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 542 | 352 | 10 |
| Full Text Views | 5 | 2 | 0 |
| PDF Downloads | 7 | 3 | 0 |